Establishment Labs ($NASDAQ:ESTA) Holdings Inc., a Costa Rica-based medical technology and aesthetics company focused on the women’s health reconstruction market, recently reported their second quarter revenue of $48.6M which surpassed the Street Estimate of $47.4M. This is a major milestone for the company as it showcases the success of their innovative medical technology and treatments that have been offered during the quarter. Establishment Labs Holdings Inc. specializes in the development and distribution of silicone breast implants, women’s health and aesthetic treatments, and medical device systems. The Motiva Implant Matrix contains a unique combination of cell and molecular components, allowing it to provide superior softness, shape stability, and tissue regeneration when compared to traditional implants.
The company has also committed to providing quality healthcare and aesthetic treatments for women worldwide. Overall, Establishment Labs Holdings Inc. has demonstrated their ability to create innovative products and provide quality treatments to women worldwide. With their second quarter revenue surpassing Street Estimates, the company can look forward to continued success in the future.
Compared to FY2022 Q1, there was a 21.1% decrease in total revenue, totaling 6.95M USD in net loss. This marks a significant milestone for ESTABLISHMENT LABS and its shareholders as it continues to post impressive profits.
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Establishment Labs. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Establishment Labs. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Establishment Labs. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Establishment Labs are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
On Tuesday, ESTABLISHMENT LABS Holdings released its financial results for the second quarter, surpassing Wall Street estimates. ESTABLISHMENT LABS Holdings attributed this strong performance primarily to increased investments in marketing and manufacturing operations. The company also noted that it had adopted new technologies and processes to increase efficiency in production, which further contributed to its higher-than-expected revenue. Live Quote…
At GoodWhale, we analyze the fundamentals of ESTABLISHMENT LABS and analyze its performance. In our Star Chart, we can see that ESTABLISHMENT LABS is strong in growth, medium in asset and weak in dividend and profitability. In terms of health, ESTABLISHMENT LABS has a low score of 2/10 considering its cashflows and debt, indicating that it is less likely to sustain future operations in times of crisis. Based on this assessment, we classify ESTABLISHMENT LABS as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. We can thus conclude that investors who are looking for high returns but with a higher risk profile might be interested in investing in ESTABLISHMENT LABS. More…
Risk Rating Analysis
Star Chart Analysis
The company has a wide array of products that cater to different needs and preferences of patients. Its main competitors are APT Medical Inc, Sisram Medical Ltd, and Vincent Medical Holdings Ltd. All of these companies offer similar products and services, but each has its own unique selling points.
APT Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for the treatment of cardiothoracic conditions. The company’s products are used by surgeons to treat a variety of conditions, including heart valve disease, coronary artery disease, and aortic aneurysms. APT Medical’s products are sold in over 50 countries around the world.
APT Medical has a market cap of $23.19 billion as of 2022 and a return on equity of 9.14%. The company’s products are used by surgeons to treat a variety of conditions, including heart valve disease, coronary artery disease, and aortic aneurysms. APT Medical’s products are sold in over 50 countries around the world.
– Sisram Medical Ltd ($SEHK:01696)
Sisram Medical Ltd is a medical device company that develops, manufactures, and markets minimally invasive solutions for the treatment of cardiovascular diseases. The company has a market cap of 2.76B as of 2022 and a return on equity of 7.2%. The company’s products are used in a variety of procedures, including angioplasty, stenting, and thrombectomy.
– Vincent Medical Holdings Ltd ($SEHK:01612)
Vincent Medical Holdings Ltd is a medical device company that designs, manufactures, and markets a range of medical devices. The company has a market capitalization of 264.6 million as of 2022 and a return on equity of -2.32%. The company’s products include anesthesia machines, blood pressure monitors, and patient monitors.
Despite this positive news, the stock price fell on the same day, indicating investors are still not fully confident in the company. To make an informed investment decision, investors need to carefully assess the financial performance of Establishment Labs and other similar companies in the women’s health reconstruction market. Factors such as R&D investments, product development, marketing strategies and competitive analysis should be considered before investing in this medical technology and aesthetics company.